Glioma clinical trials
The registry lists 1,454 studies for Glioma across more than 10 countries. 350 are recruiting or about to start. 651 of them are mainly about Glioma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 7 narrower conditions too, such as Glioblastoma: 3,405 studies, 799 open.
ClinicalTrials.gov finds 3,600 studies for Glioma. How that becomes 1,454 here
This page counts the studies the registry files under Glioma, and those it files under no condition that list Gliomathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 17, 2026. How condition pages count
- 3,600Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −1,887Filed under a narrower condition, counted on its own pageGlioblastoma 1,477 · Astrocytoma 159 · Medulloblastoma 137 · Diffuse Intrinsic Pontine Glioma 48 · Ependymoma 32 · Oligodendroglioma 17 · 1 more
- −165List Glioma as a condition, but the registry did not file them under itMost often written as “Low-Grade Glioma” (19), “Low Grade Glioma” (10), and “Low Grade Glioma of Brain” (9). The registry filed 112 of them under no condition at all, and the others under other conditions only, most often Brain Neoplasms (15) and Optic Nerve Glioma (8).
- −94Match it another way81 name it in the title, 6 in a keyword, and 7 by a synonym or other text the search reads.
- 1,454The count on this page
Get an email when these change. Save the Glioma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Status
Who runs them
National Cancer Institute (NCI) (80) · Duke University (47) · M.D. Anderson Cancer Center (30) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (26) · Memorial Sloan Kettering Cancer Center (22) · Mayo Clinic (20) · Huashan Hospital (19) · Wake Forest University Health Sciences (17)
What is being tested here
Drugs under test in Glioma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Temozolomide | 13 | 5 | 112 |
| Bevacizumab | 4 | 2 | 44 |
| Nivolumab | 4 | 0 | 13 |
| Trametinib | 4 | 1 | 11 |
| Dabrafenib | 3 | 1 | 8 |
| Vorasidenib | 3 | 2 | 7 |
| Safusidenib | 3 | 1 | 5 |
| Aminolevulinic Acid | 2 | 3 | 16 |
| Everolimus | 2 | 0 | 10 |
| Olaparib | 2 | 0 | 8 |
Drug classes tested here Alkylating agents 16 open · Tyrosine kinase inhibitors (TKIs) 9 open · Immune checkpoint inhibitors 9 open · Angiogenesis inhibitors 4 open · PARP inhibitors 4 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma · Phase 3 · Eastern Cooperative Oncology Group
- Dec 2026A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients · Phase 3 · NaviFUS Corporation
- Dec 2026Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma · Phase 3 · The Third Affiliated hospital of Zhejiang Chinese Medical University
- Apr 2027Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM · Phase 3 · Northwell Health
- Nov 2027Clinical Benefit of 18F-FET in Glioma. · Phase 3 · Primo Biotechnology Co., Ltd
- Nov 2026A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas · German Cancer Research Center
- Nov 2026A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment · Harvard Medical School (HMS and HSDM)
- Nov 2026Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery · Stanford University
- Nov 2026The circTeloDIAG: Liquid Biopsy for Glioma Tumor · Hospices Civils de Lyon
- Nov 2026Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma · Alpha Tau Medical LTD.
Who these studies take
Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 56 (21%) stop at 75 or younger. 62 (23%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 15 (6%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 54 (20%) | 54 (20%) |
| 18 | 258 (97%) | 258 (97%) |
| 30 | 243 (91%) | 243 (91%) |
| 40 | 234 (88%) | 234 (88%) |
| 50 | 235 (88%) | 235 (88%) |
| 65 | 231 (87%) | 231 (87%) |
| 75 | 222 (83%) | 222 (83%) |
| 85 | 191 (72%) | 191 (72%) |
Across all 1,454 studies, recruiting or not: 24% stop at 75 or younger and 14% at 65; 21% take children; <1% are for women only and <1% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Glioma studies take
Of 213 phase 1 interventional studies under Glioma, half reached primary completion within 59 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 59 mo36–88 · 213 studies | 62 mo42–121 · 47 studies | 59 mo36–87 · 166 studies |
| Phase 1/2 | 66 mo48–104 · 70 studies | — | 68 mo48–104 · 44 studies |
| Phase 2 | 54 mo40–88 · 131 studies | — | 55 mo41–89 · 108 studies |
| Interventional, no phase | 58 mo34–114 · 142 studies | — | 61 mo36–114 · 131 studies |
| Observational | 60 mo29–104 · 125 studies | — | 67 mo33–104 · 115 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting4
- PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging TechniqueNov 10, 2026NCT06914427
- Leica Microsystems Sponsored PMCF Study to Collect and Confirm Clinical Data on the Performance of the GLOW400 Device When Used in Accordance With Its Intended UseNov 3, 2026NCT07366892
- Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-BeingNov 3, 2026NCT07628647
- Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive DiseaseOct 20, 2026NCT07703436
Stopped1
Newly registered7
- A Phase 3, Multicenter Study of Vorasidenib in Combination With Temozolomide (TMZ) in Participants With IDH1- or IDH2 Mutant High-grade Astrocytoma.Nov 17, 2026NCT07940946
- Prospective Study of Intraoperative Brain Tumor Photographs for Pathological and Molecular ClassificationNov 16, 2026NCT07940231
- Observational Connectomics in Adults Undergoing Resection of WHO II-IV GliomaNov 10, 2026NCT07927595
- A Phase I Clinical Study of YN003 in the Treatment of GliomaNov 10, 2026NCT07929909
- Blood Brain Barrier Dysfunction in Glioma and EpileptogenesisNov 2, 2026NCT07909460
Show 2 moreShow fewer
- IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade AstrocytomasOct 22, 2026NCT07888647
- The Clinical Application Value of CAIX-Targeted PET Hypoxia Imaging in Malignant TumorsOct 22, 2026NCT07890038
Studies
Recruiting first, then most recently updated. Showing 50 of 1,454. Browse all 1,454 → or search them.
- SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)RecruitingNCT05303519Phase 39 countries
- A Phase 3, Multicenter Study of Vorasidenib in Combination With Temozolomide (TMZ) in Participants With IDH1- or IDH2 Mutant High-grade Astrocytoma.Not yet recruitingNCT07940946Phase 3
- 000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) MutationsRecruitingNCT05588141Phase 1/21 country
- Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:RecruitingNCT076080031 country
- ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade GliomasRecruitingNCT06838676Phase 25 countries
- HSV G207 in Children With Recurrent or Refractory Cerebellar Brain TumorsRecruitingNCT03911388Phase 11 country
- Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of ProgressionRecruitingNCT05565118Phase 11 country
- Prospective Study of Intraoperative Brain Tumor Photographs for Pathological and Molecular ClassificationRecruitingNCT079402311 country
- Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted SuturesRecruitingNCT07413796Not applicable1 country
- Lutathera for Treatment of Recurrent or Progressive High-Grade CNS TumorsRecruitingNCT05278208Phase 1/21 country
- PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent MedulloblastomaRecruitingNCT05096481Phase 21 country
- A Study of Mirdametinib in People With Central Nervous System TumorsRecruitingNCT07539441Phase 1/21 country
- Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIRecruitingNCT07326566Phase 21 country
- Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaRecruitingNCT07551336Phase 11 country
- Dual-Targeting CAR-NK Cell Therapy for Recurrent/Progressive Glioblastoma and High-Grade GliomaRecruitingNCT07480941Phase 11 country
- Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent GlioblastomaRecruitingNCT06910306Not applicable1 country
- Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High-grade Glioma: a Window of Opportunity Study (TARLAGLIA Study)Not yet recruitingNCT07788677Phase 11 country
- Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive DiseaseRecruitingNCT07703436Phase 21 country
- PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging TechniqueRecruitingNCT06914427Not applicable1 country
- Dabrafenib and/or Trametinib Rollover StudyRecruitingNCT03340506Phase 415 countries
- A Phase I Clinical Study of YN003 in the Treatment of GliomaRecruitingNCT07929909Phase 12 countries
- Observational Connectomics in Adults Undergoing Resection of WHO II-IV GliomaRecruitingNCT079275951 country
- Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)Not yet recruitingNCT07389278Phase 1/21 country
- Analysis of Circulating Tumor Markers in BloodRecruitingNCT04025541Not applicable1 country
- PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN AmplificationsRecruitingNCT06161519Phase 1/21 country
- Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade GliomaRecruitingNCT05717153Early Phase 11 country
- A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade GliomaRecruitingNCT07464925Phase 11 country
- Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-BeingRecruitingNCT07628647Not applicable1 country
- Leica Microsystems Sponsored PMCF Study to Collect and Confirm Clinical Data on the Performance of the GLOW400 Device When Used in Accordance With Its Intended UseRecruitingNCT073668922 countries
- Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS TumorsRecruitingNCT06528691Phase 24 countries
- Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated GliomasRecruitingNCT05804227Early Phase 11 country
- Blood Brain Barrier Dysfunction in Glioma and EpileptogenesisNot yet recruitingNCT07909460
- Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy in GliomasNot yet recruitingNCT07778979Early Phase 11 country
- IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)Not yet recruitingNCT06946680Phase 11 country
- A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)RecruitingNCT04573140Phase 11 country
- A Study of SRN-101 Administered Prior to Surgical Resection in Adults With Recurrent High-Grade Glioma.Not yet recruitingNCT07826949Phase 11 country
- 5-Aminolevulinic Acid for Photodynamic Diagnosis of Malignant GliomaRecruitingNCT06160492Phase 31 country
- A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3RecruitingNCT05916313Phase 16 countries
- VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 MutationsNot yet recruitingNCT07629089Phase 11 country
- IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade AstrocytomasNot yet recruitingNCT07888647Phase 21 country
- Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL TreatmentRecruitingNCT05460507Phase 11 country
- Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP LossRecruitingNCT06810544Phase 1/21 country
- Development of MRF for Characterization of Brain Tumors After RadiotherapyRecruitingNCT06101069Not applicable1 country
- Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)Not yet recruitingNCT07206849Phase 2
- Tumor Treating Fields for the Treatment of Brainstem GliomasRecruitingNCT05310448Not applicable1 country
- Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent GlioblastomaRecruitingNCT07416188Phase 1/21 country
- A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or FusionsRecruitingNCT06072586Early Phase 11 country
- Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent GlioblastomaRecruitingNCT06344130Phase 11 country
- Concurrent Fluorescence and Sonographically Guided Eradication of High-grade Gliomas and MetastasesRecruitingNCT05474573Not applicable1 country
- Intraoperative Brain Shift Calculation StudyRecruitingNCT05477680Not applicable1 country